Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
10.00B
Market cap10.00B
Price-Earnings ratio
-12.07
Price-Earnings ratio-12.07
Dividend yield
Dividend yield
Average volume
1.92M
Average volume1.92M
High today
$83.71
High today$83.71
Low today
$79.81
Low today$79.81
Open price
$82.68
Open price$82.68
Volume
1.41M
Volume1.41M
52 Week high
$88.31
52 Week high$88.31
52 Week low
$32.89
52 Week low$32.89

Stock Snapshot

Cytokinetics(CYTK) stock is priced at $80.36, giving the company a market capitalization of 10B. It carries a P/E multiple of -12.07.

As of 2026-07-16, Cytokinetics(CYTK) stock has fluctuated between $79.81 and $83.71. The current price stands at $80.36, placing the stock +0.7% above today's low and -4.0% off the high.

The Cytokinetics(CYTK)'s current trading volume is 1.41M, compared to an average daily volume of 1.92M.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $88.31 and a 52-week low of $32.89.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $88.31 and a 52-week low of $32.89.

CYTK News

Zacks 1d
Wall Street Analysts Think Cytokinetics Could Surge 30.54%: Read This Before Placing a Bet - Zacks Investment Research

...

Wall Street Analysts Think Cytokinetics Could Surge 30.54%: Read This Before Placing a Bet - Zacks Investment Research
Simply Wall St 1d
Cytokinetics Could Be 22% Undervalued On Its Growth Narrative

Cytokinetics (CYTK) is back in focus after president and CEO Robert I. Blum exercised options at US$10.60 and sold 7,500 shares around US$82, while retaining a...

Cytokinetics Could Be 22% Undervalued On Its Growth Narrative
Nasdaq 2d
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Key Points The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity...

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Analyst ratings

91%

of 22 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

More CYTK News

TipRanks 5d
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up

Insiders have been trading these 5 stocks: ((LRMR)), ((CYTK)), ((ITUB)), ((GLBE)) and ((IMVT)). Here is a breakdown of their recent trades and their value. Tip...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.